Pemigatinib + Afatinib in Advanced Refractory Solid Tumors (clinicaltrials.gov) - Sep 24, 2026 - P1 | N=32 | Recruiting | Sponsor: Massachusetts General Hospital | N=70 ➔ 32
Enrollment change • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • FGFR2
|